Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rich

Showing results (461-470 of 475) with videos related to

Pageof 48
Sort By:
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 26, 2023
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implicationsM L Rich, U Khan, C Zeng, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
Introducing new and repurposed TB drugs: the endTB experienceK J Seung, U Khan, F Varaine, et al.
The New England Journal of Medicine|August 9, 2008
Comprehensive treatment of extensively drug-resistant tuberculosisCarole D Mitnick, Sonya S Shin, Kwonjune J Seung, et al.
The European Respiratory Journal|November 17, 2022
European Respiratory Society guideline on various aspects of quality in lung cancer careTorsten Gerriet Blum, Rebecca L Morgan, Valérie Durieux, et al.
The New England Journal of Medicine|January 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible TuberculosisLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
The Lancet. Infectious Diseases|October 2, 2025
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosisJames A Seddon, Jay Achar, Amyn A Malik, et al.
Trials|September 26, 2021
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trialL Guglielmetti, E Ardizzoni, M Atger, et al.
Frontiers in Public Health|August 9, 2021
Integrating Health Systems and Science to Respond to COVID-19 in a Model District of Rural MadagascarRado J L Rakotonanahary, Herinjaka Andriambolamanana, Benedicte Razafinjato, et al.
The European Respiratory Journal|August 11, 2011
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 updateD Falzon, E Jaramillo, H J Schünemann, et al.
The Lancet. Respiratory Medicine|July 19, 2025
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trialLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
Pageof 48

Showing results (461-470 of 475) with videos related to

Sort By:
Pageof 48
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 26, 2023
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implicationsM L Rich, U Khan, C Zeng, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
Introducing new and repurposed TB drugs: the endTB experienceK J Seung, U Khan, F Varaine, et al.
The New England Journal of Medicine|August 9, 2008
Comprehensive treatment of extensively drug-resistant tuberculosisCarole D Mitnick, Sonya S Shin, Kwonjune J Seung, et al.
The European Respiratory Journal|November 17, 2022
European Respiratory Society guideline on various aspects of quality in lung cancer careTorsten Gerriet Blum, Rebecca L Morgan, Valérie Durieux, et al.
The New England Journal of Medicine|January 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible TuberculosisLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
The Lancet. Infectious Diseases|October 2, 2025
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosisJames A Seddon, Jay Achar, Amyn A Malik, et al.
Trials|September 26, 2021
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trialL Guglielmetti, E Ardizzoni, M Atger, et al.
Frontiers in Public Health|August 9, 2021
Integrating Health Systems and Science to Respond to COVID-19 in a Model District of Rural MadagascarRado J L Rakotonanahary, Herinjaka Andriambolamanana, Benedicte Razafinjato, et al.
The European Respiratory Journal|August 11, 2011
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 updateD Falzon, E Jaramillo, H J Schünemann, et al.
The Lancet. Respiratory Medicine|July 19, 2025
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trialLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
Pageof 48